Contraception
Volume 82, Issue 1 , Pages 41-55 , July 2010

Intrauterine device use among women with uterine fibroids: a systematic review

Received 4 February 2010 ,Accepted 4 February 2010.

References 

  1. Kaunitz A. Progestin-releasing intrauterine systems and leiomyoma. Contraception. 2007;75:S130–S133
  2. Stewart EA. Uterine fibroids. Lancet. 2001;357:293–298
  3. Stewart EA. Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas. In:  Basow D editors. UpToDate. Waltham (Mass): UpToDate; 2008;
  4. Stewart EA. Pathogenesis of uterine leiomyomas. In:  Basow D editors. UpToDate. Waltham (Mass): UpToDate; 2008;
  5. Katz V. Benign gynecologic lesions: vulva, vagina, cervix, uterus, oviduct, ovary. In:  Katz V,  Lentz GM,  Lobo RA,  Gershenson DM editor. Comprehensive gynecology. 5th ed.. Philadelphia (Pa): Mosby; 2007;
  6. Verkauf B. Myomectomy for fertility enhancement and preservation. Fertil Steril. 1992;58:1–15
  7. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–107
  8. Sivin I, Stern J. International Committee for Contraception Research (ICCR). Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. Fertil Steril. 1994;61:70–77
  9. Inki P, Hurskainen R, Palo P, et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system versus hysterectomy. Ultrasound Obstet Gynecol. 2002;20:381–385
  10. Wildemeersch D, Schacht E. The effect of menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2002;102:74–79
  11. Wildemeersch D, Schacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhea with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care. 2001;6:192–198
  12. Wildemeersch D, Schacht E, Wildemeersch P. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study. Contraception. 2002;66:93–99
  13. Wildemeersch D, Schacht E, Wildemeersch P. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception, and treatment in peri and postmenopausal women. Maturitas. 2003;44:237–245
  14. Mohllajee A, Curtis K, Flanagan R, Rinehart W, Gaffield M, Peterson H. Keeping up with evidence: a new system for WHO's evidence-based family planning guidance. Am J Prev Med. 2005;28:483–490
  15. Harris R, Helfand M, Woolf S, et al. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35
  16. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003;79:1194–1198
  17. Gunes M, Ozdegirmenci O, Kayikcioglu F, Haberal A, Kaplan M. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study. J Minim Invasive Gynecol. 2008;15:735–738
  18. Koh S, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia. J Thromb Haemost. 2007;5:133–138
  19. Magalhaes J, Mendes Aldrighi J, Rodrigues de Lima G. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007;75:193–198
  20. Mercorio F, De Simone R, Di Zpiezio Sardo A, Cerrota G, Bifulco G. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003;67:277–280
  21. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest. 2005;59:29–35
  22. Starczewski A, Iwanicki M. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekol Pol. 2000;71:1221–1225
  23. Tasci Y, Caglar G, Kayikcioglu F, Cengiz H, Yagci B, Gunes M. Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus. Arch Gynecol Obstet. 2009;280:39–42
  24. Ikomi A, Mansell E, Spence-Jones C, Singer A. Treatment of menorrhagia with the levonorgestrel intrauterine system: can we learn from our failures?. J Obstet Gynaecol. 2000;20:630–631
  25. Jindabanjerd K, Taneepanichskul S. The use of levonorgestrel-IUD in the treatment of uterine myoma in Thai women. J Med Assoc Thai. 2006;89:S147–S150
  26. Rosa e Silva JC, de Sa Rosa e Silva AC, Candido dos Reis FJ, Manetta LA, Ferriani RA, Nogueira AA. Use of a levonorgestrel-releasing intrauterine device for the symptomatic treatment of uterine myomas. J Reprod Med. 2005;50:613–617
  27. World Health Organization . Medical eligibility criteria for contraceptive use. 3rd ed.. Geneva: World Health Organization; 2004;
  28. World Health Organization . Medical eligibility criteria for contraceptive use, 2008 update. Geneva: World Health Organization; 2008;Accessed July 9, 2009. (http://whqlibdoc.who.int/hq/2008/WHO_RHR_08.19_eng.pdf)

☆ Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

PII: S0010-7824(10)00055-7

doi: 10.1016/j.contraception.2010.02.011

Contraception
Volume 82, Issue 1 , Pages 41-55 , July 2010

Article Tools